ZeptoMetrix NATtrol™ Bacteriophage MS2 quantitative stock: NATMS2-STQ is intended for use as an internal process control for molecular diagnostic assays.
The addition of the NATtrol MS2 is another great example of our commitment to the MDx industry.
BUFFALO, N.Y. (PRWEB)
July 26, 2022
ZeptoMetrix®, an Antylia Scientific™ company, today launches the NATtrol™ Bacteriophage MS2 quantitative stock: NATMS2-STQ. This product is intended for use as an internal process control for molecular diagnostic assays.
Bacteriophage MS2 is a virus that infects Escherichia coli bacteria and other members of the Enterobacteria family. It has proven utility as an internal process control for rt-PCR assays. NATtrol inactivation of MS2 results in a refrigerator-stable, whole organism stock solution which shows increased reproducibility and lot-to-lot consistency over live MS2, making it an ideal internal control for rt-PCR assays.
“The combination of our dedicated scientific consulting team and our innovative materials for assay development make ZeptoMetrix the partner of choice for molecular diagnostics developers,” said Evangeline Gonzalez, Vice President/General Manager of ZeptoMetrix. “The addition of the NATtrol MS2 is another great example of our commitment to the MDx industry.”
Find more information on the NATtrol Bacteriophage MS2 Quantitative Stock and additional ZeptoMetrix products at http://www.zeptometrix.com.
About ZeptoMetrix
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
#####
Share article on social media or email: